Plasmid DNA Manufacturing Market Growth, Revenue, Analysis, Demand and Future Outlook
Plasmid DNA Manufacturing Market Growth, Size, Trends Analysis - By Disease, By Grade, By Application, By Development Phase - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Feb-2025 | Report ID: HLCA2547 | Pages: 1 - 258 | Formats*: |
| Category : Healthcare | |||
Plasmid DNA Manufacturing Market Introduction and Overview
According to SPER Market Research, the Global Plasmid DNA Manufacturing Market is estimated to reach USD 16.07 billion by 2034 with a CAGR of 21.67%.
The report includes an in-depth analysis of the Global Plasmid DNA Manufacturing Market, including market size and trends, product mix, Applications, and supplier analysis. The global plasmid DNA manufacturing market was valued at USD 2.26 billion in 2024 and is expected to increase at a 21.67% CAGR from 2025 to 2034. Plasmid DNA is used extensively in the healthcare industry. Today, it is critical for vaccine development as well as next-generation cell and gene therapies. New plasmid DNA vaccines are now being developed, resulting in more efficient and clean manufacturing techniques. Plasmids are preferred over recombinant viruses in the manufacturing of vaccines and gene treatments because they can deliver large amounts of DNA with a low risk of oncogenesis or immunogenicity. These elements are predicted to drive industry growth.
By Disease Insights: The cancer segment had the largest market share in 2024 and is projected to experience the fastest CAGR from 2025 to 2034. The rise in using DNA plasmids for cancer treatment development is driving this growth. Strategies like genetic manipulation, immune modulation, and oncolytic virotherapy have increased the demand for plasmid DNA.
By Grade Insights: GMP-grade plasmid DNA manufacturing led the market in 2024 and is predicted to grow the fastest in the coming years. This growth is due to increased clinical development in cell and gene therapy, DNA vaccinations, and the approval of new therapies, creating high demand. Regulatory constraints on plasmid quality will further boost this segment's growth.
By Application Insights: The cell and gene therapy segment had the largest market share in 2024. This is mainly due to gene therapy being widely used for many inherited and genetic diseases, along with ongoing technological advancements for safe and effective treatments.
By Development Phase Insights: The clinical therapeutics segment had the largest market share in 2024. Plasmid DNA is becoming more important in clinical research for genetic vaccination and gene therapy. It is used for cardiovascular disorders, particularly in patients with peripheral artery disease through clinical angiogenic gene therapy, driving segment growth.
By Regional Insights: The North America Plasmid DNA manufacturing market had the largest revenue share of the global market in 2024. Key factors include a significant number of centers focused on R&D for advanced therapies. Additionally, the NIH's Recombinant DNA Advisory Committee monitors scientific, ethical, and legal issues related to rDNA techniques, helping to boost their adoption. This committee primarily reviews human gene transfer research.
Market Competitive Landscape:
Market participants in the plasmid DNA manufacturing sector are implementing new product approvals to extend the reach and availability of their products in the market, as well as expansion as a strategy to improve production/research activities. Furthermore, numerous major players are purchasing smaller competitors in order to improve their position. This strategy allows businesses to enhance their capabilities, diversify their product portfolios, and strengthen their competencies.
Recent Developments:
- BioNTech SE announced in February 2023 that it had built a new plasmid DNA manufacturing facility in Marburg, Germany. With the launch of a new manufacturing unit, the business plans to develop an autonomous facility to produce plasmid DNA for clinical product candidates as well as commercial products.
- In January 2023, KromaTiD announced the debut of a plasmid DNA manufacturing service, which is vital for the development of innovative vaccines and gene therapies.
- KromaTiD, a producer of one-of-a-kind molecular tools and services, stated in January 2023 that their plasmid services would be extended. The company has expanded its range with the inclusion of plasmid production facilities. The company's expansion is to support the commercialization of regenerative medicine.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Disease, By Grade, By Application, By Development Phase. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Charles River Laboratories, VGXI, Inc, Danaher (Aldevron), Kaneka Corp, Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Lonza, Luminous BioSciences, LLC, Akron Biotech. and others. |
Key Topics Covered in the Report:
- Global Plasmid DNA Manufacturing Market Size (FY’2021-FY’2034)
- Overview of Global Plasmid DNA Manufacturing Market
- Segmentation of Plasmid DNA Manufacturing Market By Disease (Infectious Disease, Cancer, Genetic Disorder, Others)
- Segmentation of Plasmid DNA Manufacturing Market By Grade (R&D Grade, GMP Grade)
- Segmentation of Plasmid DNA Manufacturing Market By Application (DNA Vaccines, Cell & Gene Therapy, Immunotherapy, Others)
- Segmentation of Plasmid DNA Manufacturing Market By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics)
- Statistical Snap of Global Plasmid DNA Manufacturing Market
- Expansion Analysis of Global Plasmid DNA Manufacturing Market
- Problems and Obstacles in Global Plasmid DNA Manufacturing Market
- Competitive Landscape in the Global Plasmid DNA Manufacturing Market
- Details on Current Investment in Global Plasmid DNA Manufacturing Market
- Competitive Analysis of Global Plasmid DNA Manufacturing Market
- Prominent Players in the Global Plasmid DNA Manufacturing Market
- SWOT Analysis of Global Plasmid DNA Manufacturing Market
- Globa Plasmid DNA Manufacturing Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Plasmid DNA Manufacturing Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plasmid DNA Manufacturing Market
7. Global Plasmid DNA Manufacturing Market, By Disease (USD Million) 2021-2034
7.1. Infectious Disease7.2. Cancer7.3. Genetic Disorder7.4. Others
8. Global Plasmid DNA Manufacturing Market, By Grade (USD Million) 2021-2034
8.1. R&D Grade
8.1.1. Viral Vector Development8.1.2. mRNA Development8.1.3. Antibody Development8.1.4. DNA Vaccine Development8.1.5. Others
8.2. GMP Grade
9. Global Plasmid DNA Manufacturing Market, By Application (USD Million) 2021-2034
9.1. DNA Vaccines9.2. Cell & Gene Therapy9.3. Immunotherapy9.4. Others
10. Global Plasmid DNA Manufacturing Market, By Development Phase (USD Million) 2021-2034
10.1. Pre-Clinical Therapeutics10.2. Clinical Therapeutics10.3. Marketed Therapeutics
11. Global Plasmid DNA Manufacturing Market, (USD Million) 2021-2034
11.1. Global Plasmid DNA Manufacturing Market Size and Market Share
12. Global Plasmid DNA Manufacturing Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. Charles River Laboratories
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments
13.2. VGXI Inc
13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments
13.3. Danaher (Aldevron)
13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments
13.4. Kaneka Corp
13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments
13.5. Nature Technology
13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments
13.6. Cell and Gene Therapy Catapult
13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments
13.7. Eurofins Genomics
13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments
13.8. Lonza
13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments
13.9. Luminous BioSciences, LLC
13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments
13.10. Akron Biotech
13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Plasmid DNA Manufacturing Market is projected to reach USD 16.07 billion by 2034, growing at a CAGR of 21.67% during the forecast period.
Plasmid DNA Manufacturing Market grew in Market size from 2025. The Market is expected to reach USD 16.07 billion by 2034, at a CAGR of 21.67% during the forecast period.
Plasmid DNA Manufacturing Market CAGR of 21.67% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Plasmid DNA Manufacturing Market size is USD 16.07 billion from 2025 to 2034.
Plasmid DNA Manufacturing Market is covered By Disease, By Grade, By Application, By Development Phase.
The North America is anticipated to have the highest Market share in the Plasmid DNA Manufacturing Market.
The key players in the Market include Companies Covered Charles River Laboratories, VGXI, Inc, Danaher (Aldevron), Kaneka Corp, Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Lonza, Luminous BioSciences, LLC, Akron Biotech. and others.
New plasmid DNA vaccines are now being developed, resulting in more efficient and clean manufacturing techniques. Plasmids are preferred over recombinant viruses in the manufacturing of vaccines and gene treatments because they can deliver large amounts of DNA with a low risk of oncogenesis or immunogenicity.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
